About Thermo Fisher Scientific | World Leader in Science
- Waltham, Massachusetts – February 24, 2026 – Thermo Fisher Scientific, a global leader in scientific instrumentation and services, reaffirmed its commitment to enabling advancements in science and technology,...
- The company, with annual revenue exceeding $40 billion, positions itself as a critical partner to researchers, organizations, and companies tackling some of the world’s most pressing challenges.
- “Everything we do starts with our Mission: To enable our customers to make the world healthier, cleaner and safer,” the company stated.
Waltham, Massachusetts – – Thermo Fisher Scientific, a global leader in scientific instrumentation and services, reaffirmed its commitment to enabling advancements in science and technology, according to a statement released today.
The company, with annual revenue exceeding $40 billion, positions itself as a critical partner to researchers, organizations, and companies tackling some of the world’s most pressing challenges. This includes accelerating life sciences research, refining analytical processes, and improving healthcare diagnostics and therapies.
“Everything we do starts with our Mission: To enable our customers to make the world healthier, cleaner and safer,” the company stated. This mission is underpinned by significant investment in research and development, resulting in cutting-edge technologies and services.
Thermo Fisher Scientific’s origins trace back to , though its current form emerged from the merger of Thermo Electron and Fisher Scientific. Since then, the company has grown through strategic acquisitions, including Life Technologies Corporation (), Alfa Aesar (), Affymetrix (), FEI Company (), BD Advanced Bioprocessing (), and PPD ().
The company’s expansive portfolio encompasses analytical instruments, laboratory reagents and consumables, and science software, serving a diverse range of applications in research, discovery, analysis, and manufacturing. It also provides clinical development solutions, specialty diagnostics, and pharmaceutical and biotechnology services.
According to recent financial data, Thermo Fisher Scientific reported revenue of $42.9 billion in , with an operating income of $7.34 billion and a net income of $6.34 billion. Total assets reached $97.3 billion, with total equity at $49.6 billion. The company employs approximately 125,000 people globally.
Leading the company is Marc N. Casper, Chairman, President & CEO. The leadership team also includes Stephen Williamson, Senior Vice President & Chief Financial Officer; Michel Lagarde, Executive Vice President & Chief Operating Officer; Gianluca Pettiti, Executive Vice President and President, Life Sciences, Diagnostics and Applied; Frederick M. Lowery, Executive Vice President and President, Laboratory Products and BioProduction; Mike Shafer, Executive Vice President and President, Biopharma Services; Ryan Snyder, Senior Vice President & Chief Information Officer; Lisa P. Britt, Senior Vice President & Chief Human Resource Officer; and Karen E. Nelson, Chief Scientific Officer.
Thermo Fisher Scientific operates through a number of well-recognized brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. These brands collectively provide innovative solutions aimed at improving patient outcomes, protecting the environment, and enhancing public safety.
The company’s commitment to innovation extends to a $2 billion investment over four years in the United States, as previously announced. This investment is intended to bolster domestic manufacturing and research capabilities.
The company’s recent presentation at the Raymond James Annual Institutional Investors Conference, as reported by Business Wire, underscores its ongoing engagement with the investment community and its commitment to transparency regarding its strategic direction.
Thermo Fisher Scientific’s influence extends beyond the provision of scientific tools and services. The company actively participates in addressing global challenges, including the development of plant-based food alternatives, as highlighted in recent reporting by News-Medical. This demonstrates a broadening scope of impact, extending into areas critical for sustainable food systems.
As a publicly traded company listed on the New York Stock Exchange (NYSE: TMO), Thermo Fisher Scientific is also a component of both the S&P 100 and S&P 500 indices, reflecting its significant position within the U.S. Economy. The company ranked 104th on the Fortune 500 list.
Thermo Fisher Scientific’s stated mission and ongoing investments suggest a continued focus on supporting scientific advancement and addressing global challenges in the years to come. The company’s broad portfolio and extensive reach position it as a key player in the evolving landscape of scientific research and development.